Natus Medical (NASDAQ:NTUS) posted its quarterly earnings data on Thursday. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18), MarketWatch Earnings reports. The company had revenue of $84.78 million during the quarter, compared to analyst estimates of $98.20 million. Natus Medical had a positive return on equity of 6.01% and a negative net margin of 0.18%.
Shares of NASDAQ NTUS opened at $18.58 on Friday. Natus Medical has a twelve month low of $18.33 and a twelve month high of $34.89. The company has a current ratio of 2.13, a quick ratio of 1.60 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $628.04 million, a price-to-earnings ratio of -928.54 and a beta of 0.88. The firm has a 50-day moving average of $21.42 and a two-hundred day moving average of $25.00.
Several equities research analysts recently weighed in on NTUS shares. BidaskClub downgraded shares of Natus Medical from a “sell” rating to a “strong sell” rating in a report on Friday, June 19th. Zacks Investment Research raised shares of Natus Medical from a “sell” rating to a “hold” rating in a report on Thursday, July 2nd.
Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.
Recommended Story: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.